AstraZeneca Inks $486M COVID-19 Antibody Deal With Gov't
The Trump administration announced a deal to fund two Phase 3 clinical trials of AstraZeneca's investigational COVID-19 antibody cocktail Wednesday at a total cost of $486 million as part of the...To view the full article, register now.
Already a subscriber? Click here to view full article